Enter Title

Press Release May 15, 2007    AZOPHARMA BROADENS CONTRACT PRODUCT DEVELOPMENT SERVICES WITH ADDITIONAL ACQUISITIONS U.S. based Azopharma is proud to announce newly established relationships with IQsynthesis and Cyanta Drug Development. Phil Meeks, CEO of the Azopharma Product Development Group of companies, states, "These two additions, combined with our four current companies, will round out our service offering portfolio and enhance our position as a major resource in the global contract product development arena. We are now poised to capitalize on the emerging trends transforming the pharmaceutical industry. Our entire network now consists of a family of six companies with capabilities ranging from preclinical to manufacturing. Working either individually or in conjunction, these companies offer tailored choices to the pharmaceutical and medical device industries of North America, Europe, and Asia." Phil Meeks, CEO continues, "Clients seeking contract research services and support can turn to the Azopharma Product Development Group of companies for complete solutions. This unique group of companies includes: Azopharma Contract Services - Integrated product development and CTM manufacturing - Azopharma Contract Pharmaceutical Services IQsynthesis - Synthetic chemistry services from discovery to clinical materials - IQsynthesis ApiCross Drug Delivery - Proprietary drug delivery platforms for insoluble compounds - ApiCross Drug Delivery Technologies Aniclin Preclinical Services - Preclinical services in support of early product development - AniClin Preclinical Services Cyanta Drug Development - Analytical chemistry services from development to QC testing - Cyanta Analytical Laboratories AvivoClin Clinical Services - Human clinical pharmacology services for Phase I clinical trials - AvivoClin Clinical Services "Some of our clients prefer one company managing their entire pipeline across several scientific disciplines and prefer a service provider such as Azopharma Contract Services while others prefer to outsource a single aspect of their developmental program. The latter can now turn to our other five companies depending upon their scientific needs."